2nd Quarter - Report

CGCN GROUP, LLC for SUNTORY GLOBAL SPIRITS FKA BEAM INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$30,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2021 $30,000 Replaced
2nd Quarter - Amendment Mar 22, 2022 $30,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Issues related to trade.

LobbyistCovered position, as disclosed
STEVE CLARK —
JAY CRANFORD —
SAM GEDULDIG —
AMBER KIRCHHOEFER —
MIKE NIELSEN —
TIM PATAKI New —
ALEX RENJEL —
SCOTT RIPLINGER —
JOHN STIPICEVIC —
AARON L SZABO —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Disaster Planning/Emergencies DIS

Monitor disaster relief supplementals.

LobbyistCovered position, as disclosed
STEVE CLARK —
JAY CRANFORD —
SAM GEDULDIG —
AMBER KIRCHHOEFER —
MIKE NIELSEN —
TIM PATAKI New —
ALEX RENJEL —
SCOTT RIPLINGER —
JOHN STIPICEVIC —
AARON L SZABO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Health Issues HCR

Issues related to Dietary Guidelines.

LobbyistCovered position, as disclosed
STEVE CLARK —
JAY CRANFORD —
SAM GEDULDIG —
AMBER KIRCHHOEFER —
MIKE NIELSEN —
TIM PATAKI New —
ALEX RENJEL —
SCOTT RIPLINGER —
JOHN STIPICEVIC —
AARON L SZABO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Taxation/Internal Revenue Code TAX

Monitor issues related to comprehensive tax reform, excise tax and COVID-19 response guidelines.; Monitoring issues relating to changes in excise taxes on spirits.

LobbyistCovered position, as disclosed
STEVE CLARK —
JAY CRANFORD —
SAM GEDULDIG —
AMBER KIRCHHOEFER —
MIKE NIELSEN —
TIM PATAKI New (4) Assistant to the President, Director, Office of Public Liaison, Executive Office of the President (Jan. 2019 - January 2021)
ALEX RENJEL —
SCOTT RIPLINGER —
JOHN STIPICEVIC —
AARON L SZABO —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.